



6th Paris Hepatitis Conference

Paris, 14-15 January 2013

How to optimize current therapy of non G1 Patients: Genotype 2

Alessio Aghemo

First Division of Gastroenterology

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Università degli Studi di Milano


A Bright Future For HCV-2 Patients



Some Good Reasons to Treat HCV-2 Patients Now

- HCV-2 associated with slower fibrosis progression (*Marabita, Hepatol 2011 & Bochud, J Hepatol 2009*) but also with sudden ALT flares that lead to rapid progression (*Rumi, JVH 2002 and Gut 2005*)
 - HCV-2 associated with higher risk of non Hodgkin lymphoma (*Hartridge-Lambert, Hepatology 2012*)
 - Cost and affordability of future DAAs still uncertain
-


High SVR with 24 Weeks of PegIFN plus Rbv in HCV-2 Patients




Optimization of PegIFN plus Rbv Therapy in HCV-2 Patients

Intensify Tx?


Spare AE & Costs?



Optimizing Treatment of HCV-2 Patients by Reducing PegIFN or RBV Dose




16 wks of PegIFNalpha2a plus Rbv in HCV-2 Patients: The Accelerate Study




Optimization of PegIFN plus Rbv Therapy in HCV-2 Patients

Intensify Tx?


Spare AE & Costs?



Efficacy of PegIFNalpha2a plus Rbv in 818 HCV-2 & HCV-3 Patients with Advanced Fibrosis and Cirrhosis




Optimizing Treatment of HCV-2 Patients by Using Weight Based Dosing of RBV




Does Treatment Extension to 48 Weeks Improve SVR Rates in HCV-2 Patients with Cirrhosis?

112 HCV-2 and HCV-3 pts with bridging fibrosis or cirrhosis (Hadziyannis Trial)




On-Treatment Viral Kinetics in HCV-2 Patients




RVR is The Strongest Predictor of Treatment Outcome in HCV-2 Patients

Reference	Patients	SVR	
		RVR	Non-RVR
Mangia	213	76% (40/53)	78% (45/58)
Shiffman	347	85% (210/247)	53% (53/100)
Rumi	230	83% (151/182)	52% (25/48)
Yu	150	95% (95/100)	77% (10/13)
Marcellin	1025	76% (662/858)	45% (70/157)


Response Guided Treatment Duration in RVR HCV-2 : a Meta-Analyses of RCTs




Treatment Extension to 48 wks in HCV-2/3 Without an RVR: The N-CORE Study



Response Guided Treatment Duration in HCV-2 Patients: The EASL Clinical Practice Guidelines





Do We Have Any Secret Weapons?



TVR and BOC Based Therapy in HCV-2 Patients

TVR Phase II on 23 HCV-2

BOC Phase II on 8 HCV-2



Conclusions

- The future is bright for HCV-2 patients, but the present is not so bad!
 - Optimizing treatment on baseline host and viral factors should be avoided
 - On treatment HCV RNA kinetics allow for individualized treatment schedules
-